Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study

Key Points

• To assess the long-term effectiveness and safety of atogepant in preventing migraines.
• Phase 3, open-label trial design
• Conducted over 52 weeks
• Targeted Japanese participants
• Demonstrated effectiveness in reducing migraine frequency
• Showed safety over the extended treatment period